Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson innovative Medicine depreciation and amortization ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, FY2025
3,772
Period ended Dec 28, 2025
Change on a year earlier
+0.3%
3,760 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Innovative Medicine depreciation and amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 3,772 | +0.3% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 3,760 | -2.3% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 3,847 | +4.3% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 3,687 | -8.5% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 4,029 | +0.6% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 4,006 | +2.5% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 3,910 | +2.8% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 3,802 | +57.4% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 2,416 | +172.7% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 886 | -4.6% | Form 10-K (filed 2019-02-20) ↗ |
| FY2015 | Jan 3, 2016 | 929 | – | Form 10-K (filed 2018-02-21) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Innovative Medicine depreciation and amortization ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_da_im
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.